SHIP-deficiency to increase megakaryocyte progenitor production

Details SHIP-deficiency to increase megakaryocyte progenitor production SHIP-deficiency to increase megakaryocyte progenitor production

2011-08-30

2011-08-30

Chong, Kimberly (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500, C536S024100

Reexamination Certificate

active

08008273

ABSTRACT:
The invention concerns a method for increasing megakaryocyte and megakaryocyte progenitor numbers in vitro or in vivo by suppressing SH2-containing inositol-5-phosphatase (SHIP) function in megakaryocytes or megakaryocyte progenitors expressing the SHIP gene. SHIP function can be suppressed by administering an interfering RNA, or other SHIP inhibitor, to the megakaryocytes or megakaryocyte progenitors in vitro or in vivo.

REFERENCES:
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4777127 (1988-10-01), Suni et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5804412 (1998-09-01), Gill et al.
patent: 6025198 (2000-02-01), Bennett et al.
patent: 6090621 (2000-07-01), Kavanaugh et al.
patent: 6117850 (2000-09-01), Patchen et al.
patent: 6200807 (2001-03-01), Bennett et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6703215 (2004-03-01), Erneux et al.
patent: 7691821 (2010-04-01), Desponts et al.
patent: 7713945 (2010-05-01), Kerr
patent: 7763592 (2010-07-01), Kerr et al.
patent: 7807646 (2010-10-01), Kerr et al.
patent: 2002/0137711 (2002-09-01), Kerr
patent: 2002/0165192 (2002-11-01), Kerr et al.
patent: 2003/0114401 (2003-06-01), Bennett et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0166282 (2003-09-01), Brown et al.
patent: 2004/0072298 (2004-04-01), Sauvageau et al.
patent: 2004/0235765 (2004-11-01), Kerr et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0054103 (2005-03-01), Peled et al.
patent: 2006/0223749 (2006-10-01), Desponts et al.
patent: 2007/0224124 (2007-09-01), Kerr et al.
patent: 2008/0076731 (2008-03-01), Kerr
patent: 2010/0136026 (2010-06-01), Kerr et al.
patent: 2010/0144841 (2010-06-01), Kerr
patent: 0 345 242 (1989-12-01), None
patent: 0 440 219 (1991-08-01), None
patent: 2 200 651 (1988-08-01), None
patent: WO 89/01973 (1989-03-01), None
patent: WO 91/02805 (1991-03-01), None
patent: WO 92/06693 (1992-04-01), None
patent: WO 97/10252 (1997-03-01), None
patent: WO 97/12039 (1997-04-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 02/24233 (2002-03-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/078614 (2002-10-01), None
patent: WO 2008/022468 (2008-02-01), None
patent: WO 2009/042910 (2009-04-01), None
Crooke, S.T. “Progress in Antisense Technology”Ann Rev Medicine, 2004, 55:61-95.
Jang, J.H. et al. “Gene delivery from polymer scaffolds for tissue engineering”Expert Rev. Medical Devices, 2004, 1(1):127-138.
Office Action mailed Dec. 29, 2005 in U.S. Appl. No. 09/955,174, filed Sep. 19, 2001.
Office Action mailed Aug. 9, 2005 in U.S. Appl. No. 10/605,452, filed Sep. 30, 2003.
Office Action mailed Apr. 12, 2006 in U.S. Appl. No. 10/605,542, filed Sep. 30, 2003.
Office Action mailed Sep. 28, 2009 in U.S. Appl. No. 11/451,004, filed Jun. 12, 2006.
Office Action mailed Apr. 7, 2009 in U.S. Appl. No. 11/451,004, filed Jun. 12, 2006.
Office Action mailed Aug. 5, 2008 in U.S. Appl. No. 11/451,004, filed Jun. 12, 2006.
Notice of Allowance mailed Oct. 7, 2009 in U.S. Appl. No. 11/787,064, filed Apr. 13, 2007.
U.S. Appl. No. 10/605,452, Kerr et al.
U.S. Appl. No. 10/709,801, Desponts et al.
U.S. Appl. No. 10/904,667, Kerr et al.
U.S. Appl. No. 12/670,360, Kerr et al.
U.S. Appl. No. 12/689,167, Desponts et al.
U.S. Appl. No. 12/651,809, Kerr.
Adams, A. “RNA Therapeutics Enter Clinical Trials”The Scientist, Jan. 17, 2005, 19(1):1-4.
Agrawal, S. “Antisense oligonucleotides: towards clinical trials”Tibtech, Oct. 1996, 14:376-387.
Agrawal, S. et al. “Antisense therapeutics: is it as simple as complementary base recognition”Molecular Medicine Today, Feb. 2000, 6:72-81.
Agrawal, N. et al. “RNA Interference: Biology, Mechanism, and Applications”Microbiology and Molecular Biology, Dec. 2003, 67(4):657-685.
Ahmed, N. et al. “Cytokine-Induced Expansion of Human CD34+Stem/Progenitor and CD34+CD41+Early Megakaryocytic Marrow Cells Cultured on Normal Osteoblasts”Stem Cells, 1999, 17:92-99.
Akagi, K. et al. “Cre-mediated somatic site-specific recombination in mice”Nucleic Acids Research, 1997, 25(9):1766-1773.
Bender, M.A. et al. “Description and Targeted Deletion of 5′ Hypersensitive Site 5 and 6 of the Mouse β-Globin Locus Control Region”Blood, Dec. 1998, 92(11):4394-4403.
Bjorklund, L.M. et al. “Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model” PNAS, Feb. 19, 2003, 99(4):2344-2349.
Bolland, S. et al. “SHIP Modulates Immune Receptor Responses by Regulating Membrane Association of Btk”Immunity, Apr. 1998, 8:509-516.
Bonetta, L. “RNAi: Silencing never sounded better”Nature Methods, Oct. 2004, 1(1):79-86.
Braasch, D.A. et al. “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression”Biochemistry, Apr. 9, 2002 41(14):4503-4510.
Branch, A.D. “A good antisense molecule is hard to find”TIBS, Feb. 1998, 23:45-50.
Cantley, L.C. et al. “Oncogenes and Signal Transduction”Cell, Jan. 25, 1991, 64:281-302.
Caplen, N.J. et al. “Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems”PNAS, Aug. 14, 2001, 98(17):9742-9747.
Caplen, N.J. “RNAi as a gene therapy approach”Expert Opinion Biol Ther., 2003, 3(4):575-586.
Chirila, T.V. et al. “The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides”Biomaterials, 2002, 23:321-342.
Crooke, S.T. “Basic principles of antisense therapeutics” in Antisense Research and Application, Chapter 1, pp. 1-50, S. Crooke, Editor, Springer-Verlag, 1999.
Damen, J.E. et al. “The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase”Proc Natl Acad Sci USA, Feb. 1996, 93:1689-1693.
Desponts, C. et al. “MHC Class I inhibitory receptors on natural killer cells recruit SHIP in an attempt to control cell survival”FASEB Journal, Mar. 20, 2002, 16(4):A707, abstract.
De Souza, A.T. et al, “Transcriptional and phenotypic comparisons ofPparaknockout and siRNA knockdown mice”Nucleic Acids Research, 2006, 34(16):4486-4494.
Elbashir, S.M. et al. “RNA interference is mediated by 21-and 22-nucleotide RNAs”Genes&Development, 2001, 15:188-200.
Elbashir, S.M. et al. “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”Nature, May 2001, 411:494-498.
Evans, D.J. et al. “An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies”Nature, Jun. 1989, 339:385-388.
Examination Report in European Application No. 01973144.7, dated Nov. 11, 2006.
Fire, A. et al. “Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans” Nature, Feb. 1998, 391:806-811.
Fisher-Hoch, S.P. et al. “Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene”Proc Natl Acad Sci USA, Jan. 1989, 86:317-321.
Geier, S.J. et al. “The Human SHIP Gene Is Differentially Expressed in Cell Lineages of the Bone Marrow and Blood”Blood, 1997, 89:1876-1885.
Gewirtz, A.M. et al. “Facilitating oligonucleotide delivery: Helping antisense deliver on its promise”Proc Natl Acad Sci USA, Apr. 1996, 93:3161-3163.
Ghansah, T. et al. “A role for the SH2-containing Inositol phosphatase in the biology of natural killer cells and stem cells” in Activating and inhibitory immunoglobulin-like Receptors, 2001, pp. 129-140.
Ghansah, T. et al. “Target disruption of Src homology 2-containing 5′ inositol phosphatase murine natural killer cells”FASEB Journal, Mar. 20, 2002, 16(4)

Affiliated with

Also associated with

Rating

SHIP-deficiency to increase megakaryocyte progenitor production does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SHIP-deficiency to increase megakaryocyte progenitor production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SHIP-deficiency to increase megakaryocyte progenitor production will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2649785